Stock Yearly Return 2016
Start date: 12/31/2015
End date: 12/30/2016
Start price/share: $50.68
End price/share: $7.07
Dividends collected/share: $0.00
Total return: -86.05%
Average Annual Total Return: -86.05%
Starting investment: $10,000.00
Ending investment: $1,395.00
Years: 1.00


KALV average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare KALV average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into KALV


Also see:
KALV stock yearly return 2017
KALV stock yearly return 2018
KALV stock yearly return 2019
KALV stock yearly return 2020
KALV YTD return
KALV average annual return 10 years
KalVista Pharmaceuticals is a pharmaceutical company. Co. develops a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Co. has an oral Factor XIIa inhibitor program which provides HAE therapeutics. Co. focuses on developing oral plasma kallikrein inhibitors for HAE, which includes its product candidates, KVD900, a potential oral on-demand therapy for HAE attacks; and KVD824, an oral product candidate for potential prophylactic treatment of HAE. Co.'s DME program is focused on the development of an intravitreally administered small molecule plasma kallikrein inhibitor, KVD001. The KALV stock yearly return is shown above.

The yearly return on the KALV stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2016 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the KALV annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes
Get Free SEC filing alerts for KALV:
KALV SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
KalVista Pharmaceuticals (KALV) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

KBLM Average Annual Return
KDMN Average Annual Return
KEQU Average Annual Return
KERX Average Annual Return
KIDS Average Annual Return
KIN Average Annual Return
KMPH Average Annual Return
KND Average Annual Return
KOOL Average Annual Return
KPTI Average Annual Return
More Healthcare companies »

 

KALV Stock Yearly Return 2016 | www.AverageAnnualReturn.com | Copyright © 2021 - 2021, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.